Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 11/20 | 0.67 |
| ▸ | FLT3 | P36888 | 1/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 5/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12469425 | 0.85 | BTK (0.68) | BTKFLT3HDAC4CSF1RKDR | |
| SCHEMBL1292508 | 0.84 | BTK (0.81) | BTKFLT3CSF1RKDR | |
| SCHEMBL1292450 | 0.82 | BTK (0.79) | BTKFLT3CSF1RKDR | |
| SCHEMBL12469189 | 0.82 | BTK (0.46) | BTKFLT3CSF1RKDRPIM1 | |
| SCHEMBL12469688 | 0.82 | FLT3 (0.48) | BTKFLT3CSF1R | |
| SCHEMBL29897289 | 0.80 | BTK (1.00) | BTKFLT3CSF1RKDR | |
| SCHEMBL17218915 | 0.80 | BTK (1.00) | BTKFLT3CSF1RKDR | |
| SCHEMBL12469435 | 0.80 | BTK (0.45) | BTKFLT3CSF1RKDRPIM1 | |
| SCHEMBL1292655 | 0.80 | BTK (0.88) | BTKFLT3KDR | |
| SCHEMBL7848051 | 0.79 | HDAC4 (0.49) | BTKFLT3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230012148-A1 | METHODS FOR TREATING PATIENTS WITH HEMATOLOGIC MALIGNANCIES | CRYSTALGENOMICS, INC. (KR) | 2023-01-12 | — | — | US | disclosed |
| US-20220380346-A1 | 2,3-DIHYDRO-ISOINDOLE-1-ON DERIVATIVE AS BTK KINASE SUPPRESSANT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | CRYSTALGENOMICS, INC. (KR) | 2022-12-01 | — | — | US | disclosed |
| EP-3428161-B1 | 2,3-DIHYDRO-ISOINDOLE-1-ONE DERIVATIVE AS BTK KINASE SUPPRESSANT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | CRYSTALGENOMICS INC (KR) | 2022-09-07 | — | — | EP | disclosed |
| US-11230539-B2 | 2,3-dihydro-isoindole-1-one derivative as BTK kinase suppressant, and pharmaceutical composition including same | CRYSTALGENOMICS, INC. (KR) | 2022-01-25 | — | — | US | disclosed |
| US-11230539-B2 | 2,3-dihydro-isoindole-1-one derivative as BTK kinase suppressant, and pharmaceutical composition including same | CRYSTALGENOMICS, INC. (KR) | 2022-01-25 | — | — | US | disclosed |
| EP-3886840-A1 | COMBINATION THERAPY WITH 2,3-DIHYDRO-ISOINDOLE-1-ONE COMPOUNDS AND METHODS FOR TREATING PATIENTS WITH VARIOUS MUTATIONS | Aptose Biosciences Inc. (CA) | 2021-10-06 | — | — | EP | disclosed |
| CN-113365622-A | Combination therapy using 2, 3-dihydroisoindol-1-one compounds and methods for treating patients with various mutations | 艾普托斯生物科学公司 | 2021-09-07 | — | — | CN | disclosed |
| US-20210009565-A1 | 2,3-DIHYDRO-ISOINDOLE-1-ONE DERIVATIVE AS BTK KINASE SUPPRESSANT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | CRYSTALGENOMICS, INC. (KR) | 2021-01-14 | — | — | US | disclosed |
| US-20210009565-A1 | 2,3-DIHYDRO-ISOINDOLE-1-ONE DERIVATIVE AS BTK KINASE SUPPRESSANT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | CRYSTALGENOMICS, INC. (KR) | 2021-01-14 | — | — | US | disclosed |
| WO-2020113216-A1 | COMBINATION THERAPY WITH 2,3-DIHYDRO-ISOINDOLE-1-ONE COMPOUNDS AND METHODS FOR TREATING PATIENTS WITH VARIOUS MUTATIONS | APTOSE BIOSCIENCES INC. (CA) | 2020-06-04 | — | — | WO | disclosed |
| US-20170362205-A1 | 2,3-DIHYDRO-ISOINDOLE-1-ONE DERIVATIVE AS BTK KINASE SUPPRESSANT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | CRYSTALGENOMICS, INC. (KR) | 2017-12-21 | — | — | US | disclosed |
| US-9758508-B2 | 2,3-dihydro-isoindole-1-on derivative as BTK kinase suppressant, and pharmaceutical composition including same | CRYSTALGENOMICS, INC. (KR) | 2017-09-12 | — | — | US | disclosed |
| US-9758508-B2 | 2,3-dihydro-isoindole-1-on derivative as BTK kinase suppressant, and pharmaceutical composition including same | CRYSTALGENOMICS, INC. (KR) | 2017-09-12 | — | — | US | disclosed |
| US-9758508-B2 | 2,3-dihydro-isoindole-1-on derivative as BTK kinase suppressant, and pharmaceutical composition including same | CRYSTALGENOMICS, INC. (KR) | 2017-09-12 | — | — | US | disclosed |
| US-20150336934-A1 | 2,3-DIHYDRO-ISOINDOLE-1-ON DERIVATIVE AS BTK KINASE SUPPRESSANT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | CRYSTALGENOMICS, INC. (KR) | 2015-11-26 | — | — | US | disclosed |
| US-20150336934-A1 | 2,3-DIHYDRO-ISOINDOLE-1-ON DERIVATIVE AS BTK KINASE SUPPRESSANT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | CRYSTALGENOMICS, INC. (KR) | 2015-11-26 | — | — | US | disclosed |
| US-20150336934-A1 | 2,3-DIHYDRO-ISOINDOLE-1-ON DERIVATIVE AS BTK KINASE SUPPRESSANT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | CRYSTALGENOMICS, INC. (KR) | 2015-11-26 | — | — | US | disclosed |
| EP-2940014-A1 | 2,3-DIHYDRO-ISOINDOLE-1-ON DERIVATIVE AS BTK KINASE SUPPRESSANT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | Crystalgenomics, Inc. (KR) | 2015-11-04 | — | — | EP | disclosed |
| EP-2940014-A1 | 2,3-DIHYDRO-ISOINDOLE-1-ON DERIVATIVE AS BTK KINASE SUPPRESSANT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | Crystalgenomics, Inc. (KR) | 2015-11-04 | — | — | EP | disclosed |
| WO-2012047017-A2 | 2,3-DIHYDRO-ISOINDOL-1-ONE DERIVATIVE AND A COMPOSITION COMPRISING THE SAME | 크리스탈지노믹스(주) (KR) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362205-A1 | 2,3-DIHYDRO-ISOINDOLE-1-ONE DERIVATIVE AS BTK KINASE SUPPRESSANT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | BTK, LCK, BRSK2 | BTK 1/4885FLT3 340/4885HDAC4 2411/4885 |
| US-20230012148-A1 | METHODS FOR TREATING PATIENTS WITH HEMATOLOGIC MALIGNANCIES | FLT3, BTK, MCL1 | BTK 2/4885FLT3 1/4885HDAC4 783/4885 |
| US-11230539-B2 | 2,3-dihydro-isoindole-1-one derivative as BTK kinase suppressant, and pharmaceutical composition including same | BTK, BRSK2, LCK | BTK 1/4885FLT3 286/4885HDAC4 2866/4885 |
| US-20210009565-A1 | 2,3-DIHYDRO-ISOINDOLE-1-ONE DERIVATIVE AS BTK KINASE SUPPRESSANT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | BTK, BRSK2, LCK | BTK 1/4885FLT3 286/4885HDAC4 2866/4885 |
| US-20150336934-A1 | 2,3-DIHYDRO-ISOINDOLE-1-ON DERIVATIVE AS BTK KINASE SUPPRESSANT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | BTK, LCK, BRSK2 | BTK 1/4885FLT3 319/4885HDAC4 2352/4885 |
| US-20220380346-A1 | 2,3-DIHYDRO-ISOINDOLE-1-ON DERIVATIVE AS BTK KINASE SUPPRESSANT, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | BTK, LCK, BRSK2 | BTK 1/4885FLT3 319/4885HDAC4 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.